In this issue of Industry Voice, we host Zakhar Golant, the chairman of the Union of Pharmaceutical and Clusters. We will try to find out about challenges and the purpose of running Pharmaceutical and Biomedical Clusters, learn what pharma and automotive industries have in common, and talk about market access opportunities for international pharma based on cases from companies such as Sanofi Aventis, Novo Nordisk, Novartis, Pfizer and Bayer. We will also discuss what future holds for research and development in the next 5-10 years.

0:00 Introduction
0:37 What is the main purpose of creating biopharmaceutical clusters?
2:37 Main challenges when creating clusters
5:10 International pharma in new markets: localization or market authorization?
12:00 How did key stakeholders (Ministry of Health, medical facilities, Pharma, CROs) respond to COVID-19?
16:40 Next 3-5 years in clinical research and CRO services
18:39 Pharma 2030 initiative

Enjoy and subscribe to our YouTube channel to be the first to know about new content on clinical research.

Webpage: [ Ссылка ].
Experience: [ Ссылка ].
Blog, articles, case studies: [ Ссылка ].
LinkedIn: [ Ссылка ]

✉Reach out to become the next speaker: pr@oct-clinicaltrials.com
✉Submit an RFP for clinical services: info@oct-clinicaltrials.com

#cro #octclinical

свернуть